Valuation: Modalis Therapeutics Corporation

Market Cap 351.33Cr 2.21Cr 1.94Cr 1.83Cr 1.67Cr 3.13Cr 212.14Cr 3.15Cr 22Cr 8.52Cr 107.97Cr 8.3Cr 8.12Cr P/E 2024
-3.57x
P/E 2025 -2.01x
Enterprise Value 70Cr 44.11L 38.8L 36.58L 33.37L 62.41L 42Cr 62.9L 4.39Cr 1.7Cr 22Cr 1.66Cr 1.62Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
91.39%
Yield 2024 *
-
Yield 2025 -
11/09 Exegenesis Bio and Modalis Therapeutics Corporation Collaborate To Advance MDL-201 For Duchenne Muscular Dystrophy CI
10/08 Modalis Therapeutics Corporation Reports Earnings Results for the Half Year Ended June 30, 2026 CI
12/06 Modalis Therapeutics Corporation announced that it has received ¥2.64 million in funding from Evolution Capital Management LLC CI
27/05 Modalis Therapeutics Corporation announced that it expects to receive ¥2.64 million in funding from Evolution Capital Management LLC CI
13/05 Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
12/02 Modalis Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25/25/25 Modalis Therapeutics Corporation announced that it has received ¥3.072 million in funding from Evolution Capital Management LLC CI
07/25/07 Modalis Therapeutics Corporation announced that it expects to receive ¥3.072 million in funding from Evolution Capital Management LLC CI
07/25/07 Modalis Therapeutics Licenses Gene Therapy IP from Broad Institute for Muscular Dystrophy Treatment MT
16/25/16 Modalis Issues Restricted Stock to Subsidiary Employee Under Incentive Plan MT
09/25/09 SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy CI
01/25/01 Modalis Issues 21,900 Shares for Restricted Stock Remuneration MT
27/25/27 Modalis Therapeutics Secures Japanese Patent for Gene Therapy MT
Current month-2.94%
3 months+3.12%
6 months-41.07%
Current year-41.07%
1 week 32
Extreme 32
34
1 month 32
Extreme 32
50
Current year 29
Extreme 29
83
1 year 29
Extreme 29
84
3 years 29
Extreme 29
203
5 years 29
Extreme 29
1,438
10 years 29
Extreme 29
4,070
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2016
Director of Finance/CFO 63 -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 01/01/2016
Director/Board Member 60 01/01/2016
Director/Board Member 68 01/01/2016
Date Insider Type Main position Quantity % Market Cap. Importance
24/09/24 Others

Founder

10,000 0.0220%
24/09/24 Others

Founder

10,000 0.0220%
24/09/24 Others

Founder

6,000 0.0132%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-59.76%-78.71% 2.18Cr
-3.30%+2.97%+54.99%+104.15% 7.42TCr
-0.12%-1.63%+33.14%+74.86% 5.96TCr
+2.71%-0.84%-16.39%+364.46% 2.58TCr
+0.81%+3.58%+1.01%-5.14% 2.47TCr
-1.05%+2.58%+24.27%-10.32% 2.09TCr
-1.70%-4.15%+147.82%+325.69% 1.53TCr
+2.15%+2.06%+45.57%+169.79% 1.41TCr
-0.43%-5.32%-14.46%+775.94% 1.31TCr
+0.04%-3.00%+15.76%+234.69% 1.19TCr
Average -0.09%-1.56%+23.19%+195.54% 2.6TCr
Weighted average by Cap. -0.71%-0.22%+34.91%+160.27%

Financials

2024 2025
Net sales - -
Net income -131.7Cr -82.84L -72.87L -68.69L -62.67L -1.17Cr -80Cr -1.18Cr -8.24Cr -3.19Cr -40Cr -3.11Cr -3.04Cr -215.2Cr -1.35Cr -1.19Cr -1.12Cr -1.02Cr -1.92Cr -129.94Cr -1.93Cr -13Cr -5.22Cr -66Cr -5.08Cr -4.97Cr
Net Debt -357.5Cr -2.25Cr -1.98Cr -1.86Cr -1.7Cr -3.18Cr -215.86Cr -3.21Cr -22Cr -8.67Cr -109.86Cr -8.44Cr -8.26Cr -281.2Cr -1.77Cr -1.56Cr -1.47Cr -1.34Cr -2.5Cr -169.79Cr -2.52Cr -18Cr -6.82Cr -86Cr -6.64Cr -6.5Cr
Logo Modalis Therapeutics Corporation
Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.
Employees
-
Date Price Change Volume
24/26/24 JP¥33.00 0.00% 8,86,600
18/26/18 JP¥33.00 0.00% 9,61,300
17/26/17 JP¥33.00 0.00% 8,69,500
16/26/16 JP¥33.00 +3.12% 13,45,900
15/26/15 JP¥32.00 -3.03% 18,98,000

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4883 Stock